Basic Stats
| LEI | 549300TZ84FFU2J2J459 |
| CIK | 1253689 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to GlycoMimetics, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 29, 2025 Crescent Biopharma, Inc. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-36177 06-1686563 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| July 31, 2025 |
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors Recent Leadership Appointments Bring Deep Experience in Oncology Drug Development, Clinical Operations and Building Biotechnology Companies On Track to Submit IND Application for CR-001, a PD-1 x VEGF Bispecific Antibody, in Fourth Quarter of 2025, with Proof-of-Concept Clinical Data Expected in Second Half of 2026 Waltham, Mass. |
|
| July 31, 2025 |
Crescent Biopharma, Inc. Executive Severance Plan and Form of Participation Agreement CRESCENT BIOPHARMA, INC. EXECUTIVE SEVERANCE PLAN (a.Purpose. The purpose of the Crescent Biopharma, Inc. Executive Severance Plan (the “Plan”) is to provide severance benefits to certain employees of Crescent Biopharma, Inc. and its Affiliates (as defined below) in the event of a CIC Qualifying Termination or a Qualifying Termination (each as defined below). The Plan is maintained for the purpose |
|
| June 18, 2025 |
CRESCENT’S MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.3 CRESCENT’S MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS On June 13, 2025, Gemini Merger Sub Corp. (“First Merger Sub”) merged with and into Crescent Biopharma, Inc. (“Pre-Merger Crescent”), with Pre-Merger Crescent continuing as a wholly owned subsidiary of GlycoMimetics, Inc. (“GlycoMimetics”) and the surviving corporation of the merger (the “ |
|
| June 18, 2025 |
Form of Indemnification Agreement for directors and officers. Exhibit 10.5 INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is entered into on June , 2025 by and between Crescent Biopharma, Inc. a Cayman Islands exempted company (the “Company”) and (the “Indemnitee”). Notwithstanding the date of execution of this Agreement, each of the parties hereto agrees that their respective rights, duties and obligations pursuant to this Agree |
|
| June 18, 2025 |
Exhibit 3.6 CRESCENT BIOPHARMA, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A NON-VOTING CONVERTIBLE PREFERRED SHARES Pursuant to the memorandum and articles of association of the Company, adopted by special resolution passed on 5 June 2025 and effective as of 16 June 2025 (as amended from time to time, the “Articles”). Capitalised terms not otherwise defined h |
|
| June 18, 2025 |
List of Subsidiaries of Crescent Biopharma, Inc. Exhibit 21.1 Subsidiary Country of Origin Crescent Biopharma Operating Company, LLC United States |
|
| June 18, 2025 |
CRESCENT BIOPHARMA, INC. CONDENSED BALANCE SHEETS (in thousands except share and per share amounts) Exhibit 99.2 CRESCENT BIOPHARMA, INC. CONDENSED BALANCE SHEETS (UNAUDITED) (in thousands except share and per share amounts) March 31, December 31, 2025 2024 Assets Current assets: Cash $ 22,429 $ 34,766 Prepaid expenses and other current assets 409 38 Total current assets 22,838 34,804 Other assets 2,767 813 Total assets $ 25,605 $ 35,617 Liabilities, Convertible Preferred Stock and Stockholders’ |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 Crescent Biopharma, Inc. (Exact name of Registrant as specified in its charter) Cayman Islands 001-36177 06-1686563 (State or other jurisdiction of incorporation) (Commi |
|
| June 18, 2025 |
Letter from Ernst & Young LLP, dated June 18, 2025. Exhibit 16.1 June 18, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01(a) of Form 8-K dated June 18, 2025, of Crescent Biopharma, Inc. (formerly known as GlycoMimetics, Inc.) and are in agreement with the statements contained in the first and second sentences of the first paragraph and the second, third, and fourth paragraphs the |
|
| June 18, 2025 |
Crescent Biopharma, Inc. 2025 Employee Stock Purchase Plan. Exhibit 10.8 CRESCENT BIOPHARMA, INC. 2025 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose The purpose of this Crescent Biopharma, Inc. 2025 Employee Stock Purchase Plan (the “Plan”) is to provide employees of the Company and its Designated Subsidiaries with an opportunity to purchase Ordinary Shares through accumulated Contributions. The Company’s intention is to have the Plan qualify as an “employee |
|
| June 18, 2025 |
Crescent Biopharma, Inc. 2025 Stock Incentive Plan. Exhibit 10.7 CRESCENT BIOPHARMA, INC. 2025 STOCK INCENTIVE PLAN 1. Purpose The purpose of this Crescent Biopharma, Inc. 2025 Stock Incentive Plan (the “Plan”) is to promote and closely align the interests of employees, officers, non-employee directors and other individual service providers of Crescent Biopharma, Inc. and its shareholders by providing share-based compensation and other performance- |
|
| June 18, 2025 |
Cayman Memorandum and Articles of Association. Exhibit 3.4 THE COMPANIES ACT (AS AMENDED) COMPANY LIMITED BY SHARES Memorandum OF association of CRESCENT BIOPHARMA, INC. REF: ME/KG/C9608-195644 THE COMPANIES ACT (AS AMENDED) COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF CRESCENT BIOPHARMA, INC. (ADOPTED BY SPECIAL RESOLUTION PASSED ON 5 JUNE 2025 AND EFFECTIVE AS OF 16 JUNE 2025) 1. The name of the Company is Crescent Biopharma, Inc. |
|
| June 18, 2025 |
Exhibit 99.4 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below shall have the same meaning as terms defined and included in the Company’s definitive proxy statement/prospectus filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 12, 2025. On October 28, 2024, Crescent entered into the Merger Agreement with GlycoMimetics and the Merger Su |
|
| June 18, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GLYCOMIMETICS, INC. GlycoMimetics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Company”), hereby certifies that: FIRST: The name of this Company is GlycoMimetics, Inc. SECOND: The Company’s Amended and Res |
|
| June 18, 2025 |
Exhibit 3.5 Glycomimetics, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of GlycoMimetics, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the Bo |
|
| June 18, 2025 |
Code of Business Conduct and Ethics of Crescent Biopharma, Inc. Exhibit 14.1 Code of Business Conduct and Ethics June 13, 2025 I. INTRODUCTION This Code of Business Conduct and Ethics (this “Code”) provides a general statement of the expectations of Crescent Biopharma, Inc. (the “Company”) regarding the ethical standards to which each director, officer and employee should adhere while acting on behalf of the Company. You are expected to read and become familia |
|
| June 18, 2025 |
Exhibit 3.3 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GLYCOMIMETICS, INC. GlycoMimetics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Company”), hereby certifies that: FIRST: The name of this Company is GlycoMimetics, Inc. SECOND: The Company’s Amended and Res |
|
| June 18, 2025 |
Exhibit 2.4 PLAN OF CONVERSION This Plan of Conversion (this “Plan”) is adopted as of June 16, 2025 and sets forth certain terms of the conversion of Crescent Biopharma, Inc. (formerly known as GlycoMimetics, Inc.), a Delaware corporation (the “Delaware Corporation”), to a Cayman Islands exempted company (the “Cayman Company”), pursuant to the terms of the General Corporation Law of the State of D |
|
| June 18, 2025 |
Exhibit 99.1 Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million Advancing Lead Program, CR-001, a PD-1 x VEGF Bispecific Antibody, and Developing Pipeline of Novel ADCs as Single Agents and in Combination with CR-001 On Track to Submit IND Application for CR-001 in Fourth Quarter of 2025 with Proof-of-Concept Clinical Data E |
|
| June 18, 2025 |
Exhibit 10.20 SUBLEASE This Sublease (the “Sublease”) is made as of the 28th day of May, 2025 (the “Effective Date”), by and between NANO DIMENSION USA INC., a Delaware corporation (“Sublandlord”), and CRESCENT BIOPHARMA, INC., a Delaware corporation (“Subtenant”). WITNESSETH WHEREAS, by Lease dated as of March 1, 2022, by and between NWALP PHOP PROPERY OWNER, LLC, a Delaware limited liability com |
|
| June 18, 2025 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GLYCOMIMETICS, INC. GlycoMimetics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Company”), hereby certifies that: FIRST: The name of this Company is GlycoMimetics, Inc. SECOND: The Company’s Amended and Res |
|
| June 6, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 GlycoMimetics, Inc. |
|
| June 6, 2025 |
Exhibit 99.1 GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals —GlycoMimetics Board of Directors approves 1-for-100 reverse stock split— ROCKVILLE, Md., June 5, 2025 – GlycoMimetics, Inc. (Nasdaq: GLYC) (“GlycoMimetics”) today announced that its stockholders have approved the proposed merger (the “Merger”) with Crescent Biopharma, Inc. (“Crescent” |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 GlycoMimetics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36177 06-1686563 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 GlycoMimetics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36177 06-1686563 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 29, 2025 |
Crescent Biopharma to Present at the Jefferies Global Healthcare Conference Filed by GlycoMimetics, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: GlycoMimetics, Inc. Commission File No.: 001-36177 Date: May 29, 2025 This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger and Reorganization dated as of O |
|
| May 14, 2025 |
PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT TABLE OF CONTENTS As filed pursuant to Rule 424(b)(3) Registration No. 333-285035 PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Stockholders of GlycoMimetics, Inc. and Crescent Biopharma, Inc., GlycoMimetics, Inc., a Delaware corporation (“GlycoMimetics”), and Crescent Biopharma, Inc., a Delaware corporation (“Crescent”), entered into an Agreement and Plan of Merger and Reorganization on Oc |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| May 13, 2025 |
GlycoMimetics, Inc. P.O. Box 65 Monrovia, Maryland 21770 (240) 243-1201 GlycoMimetics, Inc. P.O. Box 65 Monrovia, Maryland 21770 (240) 243-1201 May 13, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission Washington, D.C. 20549 Attention: Jessica Dickerson Re: GlycoMimetics, Inc. Registration Statement on Form S-4, as amended Filed on February 18, 2025, as amended on April 4, |
|
| May 12, 2025 |
As filed with the Securities and Exchange Commission on May 12, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 12, 2025 No. |
|
| May 12, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) GLYCOMIMETICS, INC. |
|
| May 12, 2025 |
Sidley Austin LLP 787 Seventh Avenue New York, NY 10019 +1 212 839 5300 +1 212 839 5599 Fax AMERICA · ASIA PACIFIC · EUROPE Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| April 29, 2025 |
Exhibit 10.36 CRESCENT BIOPHARMA, INC. 2024 Equity INCENTIVE PLAN 1. Purpose. The purpose of this 2024 Equity Incentive Plan (the “Plan”) of Crescent Biopharma, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Comp |
|
| April 29, 2025 |
Exhibit 10.54 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. AMENDED AND RESTATED ADC DISCOVERY AND OPTION AGREEMENT This Amended and Restated ADC Discovery and Option Agreeme |
|
| April 29, 2025 |
Exhibit 10.30 February 20, 2025 Harout Semerjian Via Email Re: Separation Agreement Dear Harout: This letter sets forth the substance of the separation agreement (the "Agreement") which GlycoMimetics, Inc. (the "Company") is offering to you to aid in your employment transition. 1. Separation Date. Your last day of work with the Company and your employment terminatio |
|
| April 29, 2025 |
Exhibit 10.1 AMENDMENT NO. 2 TO THE AGREEMENT AND PLAN OF MERGER AND REORGANIZATION This AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Amendment”) is made as of April 28, 2025, with respect to that certain Agreement and Plan of Merger and Reorganization (as amended to date, the “Merger Agreement”), dated as of October 28, 2024 (the “Agreement Date”), by and among GlycoM |
|
| April 29, 2025 |
Exhibit 10.33 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the "Agreement") by and between GlycoMimetics, Inc. ("Client") and Brian Hahn, an individual ("Consultant") is effective as of February 21, 2025 (the "Effective Date"), subject to the terms of Section 14 below. RECITALS WHEREAS the parties desire for the Client to engage Consultant to perform the services described herein and for Consul |
|
| April 29, 2025 |
Exhibit 10.32 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the "Agreement") by and between GlycoMimetics, Inc. ("Client") and Harout Semerjian, an individual ("Consultant") is effective as of February 21, 2025 (the "Effective Date"), subject to the terms of Section 14 below. RECITALS WHEREAS the parties desire for the Client to engage Consultant to perform the services described herei |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 GlycoMimetics, Inc. |
|
| April 29, 2025 |
Exhibit 10.31 February 20, 2025 Brian Hahn Via Email Re: Separation Agreement Dear Brian: This letter sets forth the substance of the separation agreement (the "Agreement") which GlycoMimetics, Inc. (the "Company") is offering to you to aid in your employment transition. 1. Separation Date. Your last day of work with the Company and your employment termination date wil |
|
| April 29, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 GlycoMimetics, Inc. |
|
| April 29, 2025 |
Amendment to the Agreement and Plan of Merger and Reorganization Exhibit 10.1 AMENDMENT NO. 2 TO THE AGREEMENT AND PLAN OF MERGER AND REORGANIZATION This AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Amendment”) is made as of April 28, 2025, with respect to that certain Agreement and Plan of Merger and Reorganization (as amended to date, the “Merger Agreement”), dated as of October 28, 2024 (the “Agreement Date”), by and among GlycoM |
|
| April 29, 2025 |
As filed with the Securities and Exchange Commission on April 28, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 28, 2025 No. |
|
| April 29, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) GLYCOMIMETICS, INC. |
|
| April 29, 2025 |
Exhibit 10.53 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. ADC DISCOVERY AND OPTION AGREEMENT This ADC Discovery and Option Agreement (“Agreement”) is entered into and effec |
|
| April 29, 2025 |
Exhibit 10.52 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. LICENSE AGREEMENT This License Agreement (“Agreement”) is entered into and effective as of April 28, 2025 (the “Ef |
|
| April 29, 2025 |
Exhibit 99.6 Consent to be Named as a Director GlycoMimetics, Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any an |
|
| April 28, 2025 |
Filed by GlycoMimetics, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: GlycoMimetics, Inc. Commission File No.: 001-36177 Date: April 28, 2025 This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger and Reorganization dated as of |
|
| April 28, 2025 |
Sidley Austin LLP 787 Seventh Avenue New York, NY 10019 +1 212 839 5300 +1 212 839 5599 Fax AMERICA • ASIA PACIFIC • EUROPE Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| April 4, 2025 |
Exhibit 10.50 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. MASTER CONTRACT SERVICES AGREEMENT THIS MASTER CONTRACT SERVICES AGREEMENT (together with Appendices A and any Sta |
|
| April 4, 2025 |
Exhibit 10.42 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. March 15, 2025 Joshua Brumm [***] Email – [***] Re: CEO Offer Letter Agreement Dear Joshua: On behalf of the Board |
|
| April 4, 2025 |
Exhibit 10.44 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. March 19, 2025 Ellie EunKyung Im Address: [***] Email: [***] Re: Offer of Employment Dear Ellie: On behalf of Cres |
|
| April 4, 2025 |
Exhibit 10.49 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. CELL LINE LICENSE AGREEMENT This Cell Line License Agreement (“Agreement”), effective as of October 31, 2024 (“EFF |
|
| April 4, 2025 |
CERTAIN PORTIONS OF THIS LETTER AS FILED VIA EDGAR HAVE BEEN OMITTED AND PROVIDED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION. |
|
| April 4, 2025 |
Exhibit 4.3 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [·] (subject to adjustment) Warrant No. [·] Original Issue Date: [·], 2025 Crescent Biopharma, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [·] or its registered assigns (the “Holder”), is entitl |
|
| April 4, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) GLYCOMIMETICS, INC. |
|
| April 4, 2025 |
Exhibit 99.5 Consent to be Named as a Director GlycoMimetics, Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any an |
|
| April 4, 2025 |
Exhibit 10.48 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. BIOLOGICS MASTER SERVICES AGREEMENT This Biologics Master Services Agreement (this “Agreement”) is dated and effec |
|
| April 4, 2025 |
Exhibit 10.43 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. March 15, 2025 Jonathan McNeill [***] Email – [***] Re: Offer of Employment Dear Jonathan: On behalf of Crescent B |
|
| April 4, 2025 |
Exhibit 10.36 CRESCENT BIOPHARMA, INC. 2024 EQUITY INCENTIVE PLAN GRANT NOTICE FOR RESTRICTED STOCK UNIT AWARD FOR GOOD AND VALUABLE CONSIDERATION, Crescent Biopharma, Inc. (the “Company”), hereby grants to the Participant named below the number of Restricted Stock Units (the “RSUs”) specified below (the “Award”) under the Crescent Biopharma, Inc. 2024 Equity Incentive Plan (the “Plan”). Each RSU |
|
| April 4, 2025 |
Exhibit 10.32 CRESCENT BIOPHARMA, INC. 2024 Equity INCENTIVE PLAN 1. Purpose. The purpose of this 2024 Equity Incentive Plan (the “Plan”) of Crescent Biopharma, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Comp |
|
| April 4, 2025 |
Sidley Austin LLP 787 Seventh Avenue New York, NY 10019 +1 212 839 5300 +1 212 839 5599 Fax AMERICA • ASIA PACIFIC • EUROPE Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| April 4, 2025 |
As filed with the Securities and Exchange Commission on April 4, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 4, 2025 No. |
|
| April 4, 2025 |
Exhibit 10.45 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. March 24, 2025 Richard Scalzo Address: [***] Email: [***] Re: Offer of Employment Dear Rick: On behalf of Crescent |
|
| April 3, 2025 |
Filed by GlycoMimetics, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: GlycoMimetics, Inc. Commission File No.: 001-36177 Date: April 3, 2025 This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger and Reorganization dated as of |
|
| April 3, 2025 |
Filed by GlycoMimetics, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: GlycoMimetics, Inc. Commission File No.: 001-36177 Date: April 3, 2025 This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger and Reorganization dated as of |
|
| February 28, 2025 |
Filed by GlycoMimetics, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: GlycoMimetics, Inc. Commission File No.: 001-36177 Date: February 28, 2025 This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger and Reorganization dated as |
|
| February 27, 2025 |
Filed by GlycoMimetics, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: GlycoMimetics, Inc. Commission File No.: 001-36177 Date: February 27, 2025 This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger and Reorganization dated as |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 GlycoMimetics, Inc. |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 GlycoMimetics, Inc. |
|
| February 18, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) GLYCOMIMETICS, INC. |
|
| February 18, 2025 |
Exhibit 10.41 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. ANTIBODY DISCOVERY AND OPTION AGREEMENT This Antibody Discovery and Option Agreement (“Agreement”) is entered into |
|
| February 18, 2025 |
Exhibit 99.1 Consent to be Named as a Director GlycoMimetics, Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any an |
|
| February 18, 2025 |
Exhibit 10.33(b) CRESCENT BIOPHARMA, INC. 2024 EQUITY INCENTIVE PLAN Restricted Stock Agreement 1. Grant of Award. (a)Award. This Restricted Stock Agreement (this “Agreement”) evidences the following grant by Crescent Biopharma, Inc., a Delaware corporation (the “Company”), of an award (this “Award”) a number of shares of Restricted Stock on the terms provided herein and in the Crescent Biopharma, |
|
| February 18, 2025 |
Exhibit 3.7 CRESCENT BIOPHARMA, INC. BYLAWS Adopted September 19, 2024 Article I STOCKHOLDERS Section 1.Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board of Directors s |
|
| February 18, 2025 |
Exhibit 99.2 Consent to be Named as a Director GlycoMimetics, Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any an |
|
| February 18, 2025 |
Exhibit 99.4 Consent to be Named as a Director GlycoMimetics, Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any an |
|
| February 18, 2025 |
Exhibit 10.39 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. November 15, 2024 Ryan Lynch [***] [residence address line 1] [***] [residence address line 2] Email: [***] Re: Of |
|
| February 18, 2025 |
As filed with the Securities and Exchange Commission on February 18, 2025 Table of Contents As filed with the Securities and Exchange Commission on February 18, 2025 No. |
|
| February 18, 2025 |
Exhibit 10.33(a) CRESCENT BIOPHARMA, INC. 2024 EQUITY INCENTIVE PLAN Restricted Stock Agreement 1. Grant of Award. (a)Award. This Restricted Stock Agreement (this “Agreement”) evidences the following grant by Crescent Biopharma, Inc., a Delaware corporation (the “Company”), of an award (this “Award”) a number of shares of Restricted Stock on the terms provided herein and in the Crescent Biopharma, |
|
| February 18, 2025 |
Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [·], 2025, is entered into by and among Crescent Biopharma, Inc., a Delaware corporation (“Crescent”), GlycoMimetics, Inc., a Delaware corporation (“Parent”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted |
|
| February 18, 2025 |
Exhibit 10.37 Consulting Agreement This Consulting Agreement (the “Agreement”) is effective as of September 28, 2024 (the “Effective Date”), Crescent Biopharma, Inc., a Delaware corporation, with a primary place of business at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (“Crescent”), and Christopher Doughty (“Consultant”). Crescent and the Consultant may be referred to herein in |
|
| February 18, 2025 |
Exhibit 10.32 CRESCENT BIOPHARMA, INC. 2024 Equity INCENTIVE PLAN 1. Purpose. The purpose of this 2024 Equity Incentive Plan (the “Plan”) of Crescent Biopharma, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Comp |
|
| February 18, 2025 |
Exhibit 10.40 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. December 20, 2024 Barbara Bispham Address: [***] Email: [***] Re: Offer of Employment Dear Barbara: On behalf of C |
|
| February 18, 2025 |
Exhibit 99.3 Consent to be Named as a Director GlycoMimetics, Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any an |
|
| February 18, 2025 |
Exhibit 10.38 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. November 27, 2024 Christopher Doughty Email – [***] Re: Offer of Employment Dear Christopher: On behalf of Crescen |
|
| February 18, 2025 |
Exhibit 10.42 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. ADC DISCOVERY AND OPTION AGREEMENT This ADC Discovery and Option Agreement (“Agreement”) is entered into and effec |
|
| February 18, 2025 |
Exhibit 10.34 Pre-IPO Form – U.S. Employees & Directors CRESCENT BIOPHARMA, INC. 2024 EQUITY INCENTIVE PLAN Stock Option Agreement [Incentive stock option // nonstatutory stock option] 1. Grant of Option. (a)This Stock Option Agreement (this “Agreement”) evidences the following grant by Crescent Biopharma, Inc., a Delaware corporation (the “Company”), of an option (this “Option”) to purchase, in w |
|
| February 18, 2025 |
Exhibit 10.36 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [·], 2024 between Crescent Biopharma, Inc., a Delaware corporation (the “Company”), and [·] (“Indemnitee”). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve companies as directors or officers, or in other capacities unless they are provided w |
|
| February 18, 2025 |
Exhibit 10.35 Consulting Agreement This Consulting Agreement (the “Agreement”) is effective as of September 28, 2024 (the “Effective Date”), Crescent Biopharma, Inc., a Delaware corporation, with a primary place of business at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (“Crescent”), and Jonathan Violin (“Consultant”). Crescent and the Consultant may be referred to herein indivi |
|
| February 18, 2025 |
Exhibit 3.6 CERTIFICATE OF INCORPORATION OF CRESCENT BIOPHARMA, INC. ARTICLE I NAME OF CORPORATION The name of this corporation (the “Corporation”) is Crescent Biopharma, Inc. ARTICLE II REGISTERED OFFICE The address of the registered office of the Corporation in the State of Delaware is Corporation Trust Company, 1209 Orange Street, in the city of Wilmington, New Castle County, Delaware 19801. Th |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 GlycoMimetics, Inc. |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 GlycoMimetics, Inc. |
|
| February 14, 2025 |
Form of Amended and Restated Securities Purchase Agreement Amended and Restated SECURITIES PURCHASE AGREEMENT This Amended and Restated SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February 14, 2025, by and among Crescent Biopharma, Inc. |
|
| February 14, 2025 |
Form of Amendment to the Agreement and Plan of Merger and Reorganization Amendment No. 1 to the Agreement and Plan of Merger AND REORGANIZATION This Amendment No. 1 to Agreement and Plan of Merger and reorganization (this “Amendment”) is made as of February 14, 2025, with respect to that certain Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), dated as of October 28, 2024 (the “Agreement Date”), by and among GlycoMimetics, Inc., a Delaware corp |
|
| February 14, 2025 |
Amended and Restated SECURITIES PURCHASE AGREEMENT This Amended and Restated SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February 14, 2025, by and among Crescent Biopharma, Inc. |
|
| February 14, 2025 |
EX-99.1 2 ex-99-02142025110235.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United State |
|
| February 14, 2025 |
Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated as of February 14, 2025 Amendment No. 1 to the Agreement and Plan of Merger AND REORGANIZATION This Amendment No. 1 to Agreement and Plan of Merger and reorganization (this “Amendment”) is made as of February 14, 2025, with respect to that certain Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), dated as of October 28, 2024 (the “Agreement Date”), by and among GlycoMimetics, Inc., a Delaware corp |
|
| February 13, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Commission file number 001-36177 GlycoMimetics, Inc. (Exact name of Registrant as specified in its charter) Delaware 06-1686563 (State or other jurisdiction of incorporati |
|
| February 13, 2025 |
Exhibit 4.2 DESCRIPTION OF CERTAIN OF REGISTRANT’S SECURITIES General The following is a summary of information concerning the capital stock of GlycoMimetics, Inc. The summaries and descriptions below do not purport to be complete statements of the relevant provisions of our amended and restated certificate of incorporation (our “restated certificate”) and amended and restated bylaws (our “restate |
|
| February 13, 2025 |
Exhibit 19.1 GLYCOMIMETICS, INC. INSIDER TRADING AND WINDOW PERIOD POLICY (Revised September 2020) I. INTRODUCTION This policy determines acceptable transactions in the securities of GLYCOMIMETICS, INC. (the “Company”) by our employees, directors and consultants. During the course of your employment, directorship or consultancy with the Company, you may receive “material” (discussed below) informa |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2025 GlycoMimetics, Inc. |
|
| January 13, 2025 |
January 2025 Crescent Biopharma Overview Exhibit 99.1 January 2025 Crescent Biopharma Overview 2 Disclaimer This presentation is for informational purposes only and only a summary of certain information related to the Company . It does not purport to be complete and does not contain all information that an investor may need to consider in making an investment decision . The information contained herein does not constitute investment, leg |
|
| January 13, 2025 |
Investor Presentation, dated January 2025 Exhibit 99.1 January 2025 Crescent Biopharma Overview 2 Disclaimer This presentation is for informational purposes only and only a summary of certain information related to the Company . It does not purport to be complete and does not contain all information that an investor may need to consider in making an investment decision . The information contained herein does not constitute investment, leg |
|
| January 13, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 GlycoMimetics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36177 06-1686563 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 GlycoMimetics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36177 06-1686563 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| December 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 GlycoMimetics, Inc. |
|
| November 27, 2024 |
GLYC / GlycoMimetics, Inc. / Logos Global Management LP Passive Investment SC 13G 1 glyc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) GlycoMimetics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 38000Q102 (CUSIP Number) November 25, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 13, 2024 |
Exhibit 10.2 Execution Version August 7, 2024 Brian Hahn RE:RETENTION AGREEMENT AND OFFER OF REVISED SEVERANCE ELIGIBILITY Dear Brian: Thank you for all of your contributions to GlycoMimetics, Inc. (the “Company”). Your role is critical to the next phase of the Company. Our hope is that, despite the fact that you may have other employment opportunities, you will remain employed with the Company un |
|
| November 13, 2024 |
Exhibit 10.3 July 30, 2024 Edwin Rock Via Email Re:Separation Agreement Dear Ed: This letter sets forth the substance of the separation agreement (the “Agreement”) which GlycoMimetics, Inc. (the “Company”) is offering to you to aid in your employment transition. 1.Separation Date. Your last day of work with the Company and your employment termination date will be July 31, 2024 (the “Separation Dat |
|
| November 13, 2024 |
Exhibit 10.1 Execution Version August 7, 2024 Harout Semerjian RE:RETENTION AGREEMENT AND OFFER OF REVISED SEVERANCE ELIGIBILITY Dear Harout: Thank you for all of your contributions to GlycoMimetics, Inc. (the “Company”). Your role is critical to the next phase of the Company. Our hope is that, despite the fact that you may have other employment opportunities, you will remain employed with the Com |
|
| November 13, 2024 |
Exhibit 10.4 Exhibit A CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) by and between GlycoMimetics, Inc. (“Client”) and Edwin Rock an individual (“Consultant”) is effective as of July 31, 2024 (the “Effective Date”), subject to the terms of Section 14 below. RECITALS WHEREAS the parties desire for the Client to engage Consultant to perform the services described herein and for Co |
|
| November 12, 2024 |
GLYC / GlycoMimetics, Inc. / Invus Global Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 d855210dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 4) GlycoMimetics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 38000Q102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check |
|
| November 7, 2024 |
Investor Presentation, dated November 2024 Exhibit 99.1 November 2024 Crescent Biopharma Overview 2 Disclaimer This presentation is for informational purposes only and only a summary of certain information related to the Company . It does not purport to be complete and does not contain all information that an investor may need to consider in making an investment decision . The information contained herein does not constitute investment, le |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 GlycoMimetics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36177 06-1686563 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 7, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 GlycoMimetics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36177 06-1686563 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 7, 2024 |
November 2024 Crescent Biopharma Overview Exhibit 99.1 November 2024 Crescent Biopharma Overview 2 Disclaimer This presentation is for informational purposes only and only a summary of certain information related to the Company . It does not purport to be complete and does not contain all information that an investor may need to consider in making an investment decision . The information contained herein does not constitute investment, le |
|
| November 6, 2024 |
EX-1 2 tm2427451d3ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 6, 2024 is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a s |
|
| November 6, 2024 |
GLYC / GlycoMimetics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GlycoMimetics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 38000Q102 (CUSIP Number) October 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| November 4, 2024 |
GLYC / GlycoMimetics, Inc. / Adage Capital Management, L.P. - GLYCOMIMETICS INC Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* GlycoMimetics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 38000Q102 (CUSIP Number) Robert Atchinson Adage Capital Partners GP, L.L.C. 200 Clarendon Street, 52nd Floor Boston, MA 02116 (617) 867-2800 (Name, Address and |
|
| November 4, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned ackn |
|
| October 29, 2024 |
Form of Registration Rights Agreement Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [•], 2025, is entered into by and among GlycoMimetics, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used herein |
|
| October 29, 2024 |
Exhibit 99.1 GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint ROCKVILLE, Md.-(BUSINESS WIRE)— October 29, 2024- GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the Phase 2 analysis of the adaptiv |
|
| October 29, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: GlycoMimetics, Inc. GEMINI MERGER SUB CORP.; GEMINI Merger Sub II, LLC; and Crescent Biopharma, Inc. Dated as of October 28, 2024 Table of Contents Section 1. Definitions and Interpretative Provisions. 3 1.1 Definitions 3 1.2 Other Definitional and Interpretative Provisions 20 Section 2. Description of Transaction 21 2.1 The Merger |
|
| October 29, 2024 |
Joint Press Release, issued on October 29, 2024 Exhibit 99.2 GlycoMimetics enters into acquisition agreement with Crescent Biopharma Following closing, the combined company will advance Crescent’s portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors Crescent’s lead program CR-001, a tetravalent PD-1 x VEGF bispecific antibody incorporating the cooperative binding mechanism underpinning recent immuno-onc |
|
| October 29, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: GlycoMimetics, Inc. GEMINI MERGER SUB CORP.; GEMINI Merger Sub II, LLC; and Crescent Biopharma, Inc. Dated as of October 28, 2024 Table of Contents Section 1. Definitions and Interpretative Provisions. 3 1.1 Definitions 3 1.2 Other Definitional and Interpretative Provisions 20 Section 2. Description of Transaction 21 2.1 The Merger |
|
| October 29, 2024 |
Form of GlycoMimetics Securities Purchase Agreement Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 28, 2024, by and among GlycoMimetics, Inc., a Delaware corporation (the “Company”), and each of the Persons listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and delivering this |
|
| October 29, 2024 |
Exhibit 3.1 Glycomimetics, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of GlycoMimetics, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the Bo |
|
| October 29, 2024 |
CONFIDENTIAL October 2024 Crescent Biopharma Confidential Overview Exhibit 99.3 CONFIDENTIAL October 2024 Crescent Biopharma Confidential Overview 2 Disclaimer CONFIDENTIAL This presentation is strictly confidential and being made to you solely as a prospective investor in the proposed offering (the “Offering”) of common stock, par value $ 0 . 001 per share, or, in lieu thereof, pre - funded warrants (together, the “Securities”) of GlycoMimetics , Inc . (the “we, |
|
| October 29, 2024 |
Form of GlycoMimetics Support Agreement Exhibit 10.2 SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made and entered into as of [·], 2024, by and among Crescent Biopharma, Inc., a Delaware corporation (the “Company”), GlycoMimetics, Inc., a Delaware corporation (“Parent”), and the undersigned stockholder (the “Stockholder” and each of the Stockholder, Company, and Parent a “Party” and, collectively, the “Parties”) of the |
|
| October 29, 2024 |
Exhibit 10.5 LOCK-UP AGREEMENT October [·], 2024 GlycoMimetics, Inc., 9708 Medical Center Drive Rockville, Maryland 20850 Attention: Christian Dinneen-Long Email: [email protected] Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that GlycoMimetics, Inc., a Delaware corporation (“Parent”), has entered into an Agreement a |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 GlycoMimetics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36177 06-1686563 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 GlycoMimetics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36177 06-1686563 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| October 29, 2024 |
Press Release, issued on October 29, 2024 Exhibit 99.1 GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint ROCKVILLE, Md.-(BUSINESS WIRE)— October 29, 2024- GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the Phase 2 analysis of the adaptiv |
|
| October 29, 2024 |
Form of Crescent Support Agreement Exhibit 10.1 SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made and entered into as of October [·], 2024, by and among Crescent Biopharma, Inc., a Delaware corporation (the “Company”), GlycoMimetics, Inc., a Delaware corporation (“Parent”), and the undersigned stockholder (the “Stockholder” and each of the Stockholder, Company, and Parent a “Party” and, collectively, the “Parties” |
|
| October 29, 2024 |
Exhibit 99.2 GlycoMimetics enters into acquisition agreement with Crescent Biopharma Following closing, the combined company will advance Crescent’s portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors Crescent’s lead program CR-001, a tetravalent PD-1 x VEGF bispecific antibody incorporating the cooperative binding mechanism underpinning recent immuno-onc |
|
| October 29, 2024 |
Form of Crescent Support Agreement Exhibit 10.1 SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made and entered into as of October [·], 2024, by and among Crescent Biopharma, Inc., a Delaware corporation (the “Company”), GlycoMimetics, Inc., a Delaware corporation (“Parent”), and the undersigned stockholder (the “Stockholder” and each of the Stockholder, Company, and Parent a “Party” and, collectively, the “Parties” |
|
| October 29, 2024 |
Form of GlycoMimetics Support Agreement Exhibit 10.2 SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made and entered into as of [·], 2024, by and among Crescent Biopharma, Inc., a Delaware corporation (the “Company”), GlycoMimetics, Inc., a Delaware corporation (“Parent”), and the undersigned stockholder (the “Stockholder” and each of the Stockholder, Company, and Parent a “Party” and, collectively, the “Parties”) of the |
|
| October 29, 2024 |
Exhibit 10.5 LOCK-UP AGREEMENT October [·], 2024 GlycoMimetics, Inc., 9708 Medical Center Drive Rockville, Maryland 20850 Attention: Christian Dinneen-Long Email: [email protected] Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that GlycoMimetics, Inc., a Delaware corporation (“Parent”), has entered into an Agreement a |
|
| October 29, 2024 |
Exhibit 99.4 CORPORATE PARTICIPANTS Harout Semerjian President & Chief Executive Officer, GlycoMimetics, Inc. Jonathan Violin, PhD Chief Executive Officer, CRESCENT Biopharma, Inc. MANAGEMENT DISCUSSION SECTION Operator: Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the GlycoMimetics-CRESCENT Biopharma Transaction Conference Call. I would also like to remind you that th |
|
| October 29, 2024 |
Exhibit 3.1 Glycomimetics, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of GlycoMimetics, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the Bo |
|
| October 29, 2024 |
Investor Presentation, dated October 2024 Exhibit 99.3 CONFIDENTIAL October 2024 Crescent Biopharma Confidential Overview 2 Disclaimer CONFIDENTIAL This presentation is strictly confidential and being made to you solely as a prospective investor in the proposed offering (the “Offering”) of common stock, par value $ 0 . 001 per share, or, in lieu thereof, pre - funded warrants (together, the “Securities”) of GlycoMimetics , Inc . (the “we, |
|
| October 29, 2024 |
Conference Call Transcript dated October 29, 2024 Exhibit 99.4 CORPORATE PARTICIPANTS Harout Semerjian President & Chief Executive Officer, GlycoMimetics, Inc. Jonathan Violin, PhD Chief Executive Officer, CRESCENT Biopharma, Inc. MANAGEMENT DISCUSSION SECTION Operator: Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the GlycoMimetics-CRESCENT Biopharma Transaction Conference Call. I would also like to remind you that th |
|
| October 29, 2024 |
Form of GlycoMimetics Securities Purchase Agreement Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 28, 2024, by and among GlycoMimetics, Inc., a Delaware corporation (the “Company”), and each of the Persons listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and delivering this |
|
| October 29, 2024 |
Form of Registration Rights Agreement Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [•], 2025, is entered into by and among GlycoMimetics, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used herein |
|
| August 15, 2024 |
GLYC / GlycoMimetics, Inc. / Invus Global Management, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 3) GlycoMimetics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 38000Q102 (CUSIP Number) August 13, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| July 30, 2024 |
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan Exhibit 99.1 GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan ● After meeting with the U.S Food and Drug Administration (FDA), it has been determined that the regulatory path forward for uproleselan in relapsed and refractory (R/R) Acute Myeloid Leukemia (AML) would require an additional clinical trial ● The Company will conduct a strategic review of the business seeking t |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 GlycoMimetics, Inc. |
|
| July 29, 2024 |
EX-99.1 2 d810309dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the securities of GlycoMimetics, Inc. is, and any amendments thereto signed by each or any of the undersigned shall be, filed on behalf of each of such person pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Ac |
|
| July 29, 2024 |
GLYC / GlycoMimetics, Inc. / Invus Global Management, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) GlycoMimetics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 38000Q102 (CUSIP Number) July 25, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| June 26, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 GlycoMimetics, Inc. |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 GlycoMimetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36177 06-1686563 (State or other jurisdiction of incorporation) (Commission File |
|
| June 4, 2024 |
Exhibit 99.1 GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) • Company exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinically meaningful results in primary refractory AML, and significant unmet patient need • Uproleselan demonstrated a |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 GlycoMimetics, Inc. |
|
| June 4, 2024 |
Exhibit 99.2 Results of Pivotal Phase 3 Trial of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) June 2024 | NASDAQ: GLYC 2 • To the extent that statements contained in this presentation are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of the management of GlycoMimetics, Inc. (“GlycoMimetics,” “we,” |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| May 8, 2024 |
SC 13D/A 1 nea10-glyco18835.htm NEW ENTERPRISE ASSOCIATES 10, L.P. / GLYCOMIMETICS - SCHEDULE 13D/A(#4E) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* GlycoMimetics, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 38000Q102 (CUSIP Number) Stephanie Brecher New Ente |
|
| May 6, 2024 |
Exhibit 99.2 Transforming Lives Glycobiology-based Therapeutics May 2024 | NASDAQ: GLYC 2 Forward-Looking Statements • To the extent thatstatements contained in this presentation are not descriptions of historical facts,they are forward-looking statementsreflecting the current beliefs and expectations of the management of GlycoMimetics, Inc. (“GlycoMimetics,” “we,” “us,” or “our”). Forward-looking |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 GlycoMimetics, Inc. |
|
| May 6, 2024 |
Exhibit 99.1 GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) ● Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population ● Adverse events were consistent with known side effect profiles of chemotherapy used in the study ● Comprehensive data |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 GlycoMimetics, Inc. |
|
| May 2, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF GLYCOMIMETICS, INC. GlycoMimetics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Company”), hereby certifies that: FIRST: The name of this Company is GlycoMimetics, Inc. SECOND: The Company’s original Certificate of Incorporation was filed on Ap |
|
| May 2, 2024 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF GLYCOMIMETICS, INC. GlycoMimetics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Company”), hereby certifies that: FIRST: The name of this Company is GlycoMimetics, Inc. SECOND: The Company’s original Certificate of Incorporation was filed on Ap |
|
| April 1, 2024 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 27, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-8 GLYCOMIMETICS, INC. |
|
| March 27, 2024 |
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 EXHIBIT 99.1 GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 ● Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) to be reported in Q2 2024 ● New Drug Application (NDA) for uproleselan to be submitted to the U.S. Food and Drug Administration (FDA) by end of 2024 if outcome of R/R AML pivot |
|
| March 27, 2024 |
Exhibit 10.20 Certain identified information has been excluded from the exhibit because it is both not material and is the type that the Registrant treats as private or confidential. Triple asterisks [***] denote exclusions. PROJECT AGREEMENT PROJECT AGREEMENT FOR COMMERCIAL SERVICES UNDER THE MASTER SERVICES AGREEMENT DATED JULY 11, 2023, BETWEEN PATHEON MANUFACTURING SERVICES LLC (“PATHEON”) AND |
|
| March 27, 2024 |
Exhibit 10.16 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 20 day of April, 2018 (“Second Amendment Execution Date”), by and between BMR-MEDICAL CENTER DRIVE LLC, a Delaware limited liability company (“Landlord), and GLYCOMIMETICS, INC., a Delaware corporation (“Tenant”). RECITALS A.WHEREAS, Landlord and Tenant are parties to that certain L |
|
| March 27, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number 001-36177 GlycoMimetics, Inc. (Exact name of Registrant as specified in its charter) Delaware 06-1686563 (State or other jurisdiction of incorporati |
|
| March 27, 2024 |
Incentive Compensation Recoupment Policy. Exhibit 97.1 GLYCOMIMETICS, INC. Incentive Compensation Recoupment Policy 1.Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of GlycoMimetics, Inc., a Delaware corporation (the “Company”), and the Board have determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Po |
|
| March 27, 2024 |
As filed with the Securities and Exchange Commission on March 27, 2024 As filed with the Securities and Exchange Commission on March 27, 2024 Registration No. |
|
| March 27, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 GlycoMimetics, Inc. |
|
| March 27, 2024 |
Exhibit 10.13 GlycoMimetics, Inc. Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of GlycoMimetics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation |
|
| March 22, 2024 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 1, 2024 |
Exhibit 99.1 Transforming Lives Glycobiology-based Therapeutics March 2024 | NASDAQ: GLYC Exhibit 99.1 2 • To the extent that statements contained in this presentation are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of the management of GlycoMimetics, Inc. (“GlycoMimetics,” “we,” “us,” or “our”). Forward-looking statemen |
|
| March 1, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2024 GlycoMimetics, Inc. |
|
| February 29, 2024 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* GlycoMimetics, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 38000Q102 (CUSIP Number) Stephanie Brecher New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name |
|
| February 12, 2024 |
SC 13D/A 1 nea10-glyco18796.htm NEW ENTERPRISE ASSOCIATES 10, L.P. / GLYCOMIMETICS - SCHEDULE 13D/A(#2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* GlycoMimetics, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 38000Q102 (CUSIP Number) Stephanie Brecher New Enter |
|
| February 9, 2024 |
GLYC / GlycoMimetics, Inc. / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 1) GlycoMimetics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 38000Q102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| January 29, 2024 |
SC 13G/A 1 sc13ga407422glyc01292024.htm AMENDMENT NO. 4 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 GlycoMimetics, Inc. (Name of Issuer) Common Stock, $0.001 par valu |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 GlycoMimetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36177 06-1686563 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 GlycoMimetics, Inc. |
|
| November 3, 2023 |
Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.1 GlycoMimetics, Inc. Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of GlycoMimetics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation |
|
| November 3, 2023 |
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023 EXHIBIT 99.1 GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023 ● Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) on track to be reported by end of Q2 2024 ● NDA filing for uproleselan anticipated by end of 2024 pending outcome of R/R AML pivotal study ● Initial results for GMI-1687 Phase 1a study expect |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| August 2, 2023 |
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023 EXHIBIT 99.1 GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023 ● Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) expected by end of Q2 2024 after addition of time-based analysis option ● U.S. Food and Drug Administration (FDA) agrees to initial Pediatric Study Plan (iPSP) for uproleselan, and National |
|
| August 2, 2023 |
Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.1 GlycoMimetics, Inc. Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of GlycoMimetics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation |
|
| August 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 GlycoMimetics, Inc. |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2023 GlycoMimetics, Inc. |
|
| May 3, 2023 |
Consulting Agreement dated March 31, 2023, by and between the Company and John Magnani, Ph.D. Exhibit 10.3 Consulting Agreement This Consulting Agreement (the “Agreement”) by and between GlycoMimetics, Inc. (“Client”) and John Magnani, Ph.D., an individual (“Consultant”) is effective as of March 31, 2023 (the “Effective Date”). RECITALS WHEREAS the parties desire for the Client to engage Consultant to perform the services described herein and for Consultant to provide such services on the |
|
| May 3, 2023 |
Transition Agreement dated February 21, 2023, by and between the Company and John Magnani, Ph.D. Exhibit 10.2 February 14, 2023 Modified February 21, 2023 John Magnani, Ph.D. 12819 Doe Lane Gaithersburg MD 20878 E-mail: [email protected] Re:Transition Agreement Dear John: This letter sets forth the substance of the Transition Agreement (the “Transition Agreement” or “Agreement”) which GlycoMimetics, Inc. (the “Company”) is offering to you. 1.Transition Services. If you execute this A |
|
| May 3, 2023 |
Exhibit 10.5 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective February 10, 2023 (the “Effective Date”), by and between Chinmaya Rath and GlycoMimetics, Inc. (the “Company”). WHEREAS, the Company desires to employ Executive to provide personal services to the Company, and Executive wishes to continue to be employed by the Company and pro |
|
| May 3, 2023 |
Release Agreement, dated February 13, 2023, by and between the Company and Armand Girard. Exhibit 10.1 Release Agreement This Release Agreement (“Release”) is made by and between GlycoMimetics, Inc. (the “Company”) and Armand Girard (“you”). You and the Company entered into an Amended and Restated Employment Agreement dated July 30, 2019 (the “Employment Agreement”). You and the Company hereby further agree as follows: 1.A blank copy of this Release was attached to the Employment Agree |
|
| May 3, 2023 |
Exhibit 10.4 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective February 16, 2022 (the “Effective Date”), by and between Bruce Johnson and GlycoMimetics, Inc. (the “Company”). WHEREAS, the Company desires to employ Executive to provide personal services to the Company, and Executive wishes to continue to be employed by the Company and pro |
|
| May 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 GlycoMimetics, Inc. |
|
| May 3, 2023 |
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023 EXHIBIT 99.1 GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023 ● Pivotal Phase 3 study of uproleselan combined with cytarabine-based chemotherapy in relapsed/refractory (R/R) acute myeloid leukemia (AML) continues to be projected to reach final survival event trigger within first half of 2024 ● Cash and cash equivalents expected to fund current operations into late 4th |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2023 GlycoMimetics, Inc. |
|
| April 21, 2023 |
Exhibit 10.1 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (“this Third Amendment”) is made as of this 19 day of April, 2023 (“Effective Date”), between ARE-MARYLAND NO. 45, LLC, a Delaware limited liability company, having an address at 26 North Euclid Avenue, Pasadena, California 91101 (“Landlord”), and GLYCOMIMETICS, INC., a Delaware corporation, having an address at 9708 Medical Cente |
|
| April 21, 2023 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 29, 2023 |
Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.14 GlycoMimetics, Inc. Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of GlycoMimetics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation |
|
| March 29, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Commission file number 001-36177 GlycoMimetics, Inc. (Exact name of Registrant as specified in its charter) Delaware 06-1686563 (State or other jurisdiction of incorporati |
|
| March 29, 2023 |
As filed with the Securities and Exchange Commission on March 29, 2023 As filed with the Securities and Exchange Commission on March 29, 2023 Registration No. |
|
| March 29, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 GlycoMimetics, Inc. |
|
| March 29, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-8 GLYCOMIMETICS, INC. |
|
| March 29, 2023 |
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022 EXHIBIT 99.1 GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022 ● Significant progress in strengthening leadership, raising capital, and preparing for final results of the uproleselan Phase 3 study in relapsed/refractory (R/R) acute myeloid leukemia (AML) ● Interim utility analysis used high statistical threshold and resulted in independent Data Monitoring |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 GlycoMimetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36177 06-1686563 (State or other jurisdiction of incorporation) (Commission File |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 GlycoMimetics, Inc. |
|
| March 2, 2023 |
Exhibit 99.1 © 2021 GlycoMimetics, Inc. All rights reserved. Glycobiology-based therapeutics Transforming lives NASDAQ: GLYC March 2023 • To the extent that statements contained in this presentation are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of the management of GlycoMimetics, Inc. (“GlycoMimetics,” “we,” “us,” or “ |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 GlycoMimetics, Inc. |
|
| February 13, 2023 |
GLYC / GlycoMimetics Inc / Artal International S.C.A. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. ) GlycoMimetics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 38000Q102 (CUSIP Number) February 9, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 13, 2023 |
EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the Common Stock, $0.001 par value per share, of GlycoMimetics, Inc. is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, |
|
| February 10, 2023 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* GlycoMimetics, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 38000Q102 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 ( |
|
| November 9, 2022 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of August 31, 2022, by and between Ed Rock, M.D., and GlycoMimetics, Inc. (the “Company”). WHEREAS, the Company desires to employ Executive to provide personal services to the Company, and Executive wishes to continue to be employed by the Company and provide personal services to th |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 GlycoMimetics, Inc. |
|
| November 9, 2022 |
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022 EXHIBIT 99.1 GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022 ● U.S. Food and Drug Administration (FDA) clears protocol amendment to conduct an interim utility analysis of pivotal Phase 3 study of uproleselan in relapsed/refractory acute myeloid leukemia (AML) ● Blinded pooled survival data show patients in the Phase 3 study continue to live longer than historically ex |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| October 4, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): October 4, 2022 ? ? GlycoMimetics, Inc. |
|
| October 4, 2022 |
Exhibit 99.1 ?2021 GlycoMimetics, Inc. All rights reserved. Glycobiology-based therapeuticsTransforming livesOctober 2022 Corporate Presentation NASDAQ: GLYC ?To the extent that statements contained in this presentation are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of the management of GlycoMimetics, Inc. (?GlycoMimeti |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 GlycoMimetics, Inc. |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| August 3, 2022 |
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022 EXHIBIT 99.1 GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022 ● U.S. Food and Drug Administration (FDA) Clearance of Investigational New Drug (IND) application to study GMI-1687 in Sickle Cell Disease (SCD) received in June ● The Company previously disclosed and will continue to update its projection of mid-year 2023 for the survival events trigger for its pivotal Pha |
|
| June 3, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): May 31, 2022 ? ? GlycoMimetics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware ? 001-36177 ? 06-1686563 (State or other jurisdiction of inc |
|
| May 20, 2022 |
GlycoMimetics, Inc. Amended and Restated 2013 Equity Incentive Plan. Exhibit 10.1 GLYCOMIMETICS, INC. AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: APRIL 7, 2022 APPROVED BY THE STOCKHOLDERS: May 18, 2022 EFFECTIVE DATE OF AMENDMENT AND RESTATEMENT: April 7, 2022 1.?????????????General. (a)???????????Successor to Prior Plan. The Plan is intended as the successor to the GlycoMimetics, Inc. 2003 Stock Incentive Plan, |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 GlycoMimetics, Inc. |
|
| April 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): April 28, 2022 ? ? GlycoMimetics, Inc. |
|
| April 28, 2022 |
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2022 EXHIBIT 99.1 ? ? GlycoMimetics Reports Highlights and Financial Results for First Quarter 2022 ? ? Mid-year 2023 projected for events trigger of the GlycoMimetics-sponsored pivotal Phase 3 trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML). ? Investigational new drug (IND)-enabling 28-day toxicity studies and GMP manufacturing completed for GMI-1687 for |
|
| April 28, 2022 |
424B5 1 tm2213846-1424b5.htm 424B5 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-263297 PROSPECTUS SUPPLEMENT $100,000,000 Common Stock We have entered into a certain Sales Agreement, or the sales agreement, with Cowen and Company, LLC, or Cowen, dated as of April 28, 2022, relating to shares of our common stock offered by this prospectus supplement. In accord |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 28, 2022 |
Exhibit 10.1 GLYCOMIMETICS, INC. Common Stock (par value $0.001 per share) SALES AGREEMENT ? April 28, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 ? Ladies and Gentlemen: ? GlycoMimetics, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agree |
|
| April 20, 2022 |
April 20, 2022 VIA EDGAR Alan Campbell Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 11, 2022 |
our Proxy Statement filed with the SEC on April 11, 2022, SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 4, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.5 GlycoMimetics, Inc. AND [], As Warrant Agent Form of Preferred Stock Warrant Agreement Dated As Of GlycoMimetics, Inc. Form of Preferred Stock Warrant Agreement This Preferred Stock Warrant Agreement (this ?Agreement?), dated as of [?], between GlycoMimetics, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing und |
|
| March 4, 2022 |
Calculation of Filing Fee Tables EX-FILING FEES 8 tm228110d2ex107.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) GlycoMimetics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (a) Proposed Maximum Offering Price Per Unit Maximum Aggregat |
|
| March 4, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.4 GlycoMimetics, INC. AND , As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of GlycoMimetics, Inc. Form of Common Stock Warrant Agreement This Common Stock Warrant Agreement (this ?Agreement?), dated as of [?], between GlycoMimetics, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the laws |
|
| March 4, 2022 |
As filed with the Securities and Exchange Commission on March 4, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 4, 2022 Registration No. |
|
| March 4, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.6 GlycoMimetics, Inc. AND [], As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of [] GlycoMimetics, Inc. Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this ?Agreement?), dated as of [?], between GlycoMimetics, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing |
|
| March 4, 2022 |
Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.2 GLYCOMIMETICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities Table of Contents Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Trustee?s Certificate 6 Sectio |
|
| March 3, 2022 |
Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.14 ? GLYCOMIMETICS, INC. ? AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ? Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of GlycoMimetics, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Amended and Restated Non-Employee Director Compen |
|
| March 3, 2022 |
Exhibit 10.19 GLYCOMIMETICS, INC. AMENDED AND RESTATED INDUCEMENT PLAN 1.GENERAL. (a)Eligible Stock Award Recipients. The only persons eligible to receive grants of Stock Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1 ? that is, generally, a person not previously an empl |
|
| March 3, 2022 |
As filed with the Securities and Exchange Commission on March 3, 2022 S-8 1 tmb-20220303xs8.htm S-8 As filed with the Securities and Exchange Commission on March 3, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GlycoMimetics, Inc. (Exact name of Registrant as specified in its charter) Delaware 06-1686563 (State or other jurisdiction of Incorporation |
|
| March 3, 2022 |
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2021 EXHIBIT 99.1 ? GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2021 ? ? Post year-end 2022 remains target for top-line data release of GlycoMimetics-sponsored pivotal Phase 3 trial evaluating uproleselan in relapsed/refractory acute myeloid leukemia (AML) ? National Cancer Institute (NCI) to conduct post-Phase 2 interim analysis based on event-free survival |
|
| March 3, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Commission file number 001-36177 GlycoMimetics, Inc. (Exact name of Registrant as specified in its charter) ? Delaware 06-1686563 (State or other jurisdiction of incorpora |
|
| March 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): March 3, 2022 ? ? GlycoMimetics, Inc. |
|
| March 3, 2022 |
Consulting Agreement, dated as of August 31, 2021, by and between the Registrant and Rachel King ? Exhibit 10.13 ? CONSULTING AGREEMENT ? THIS CONSULTING AGREEMENT (the ?Agreement?) by and between GlycoMimetics, Inc. (?Client?) and Rachel K. King, an individual (?Consultant?) is effective as of August 31, 2021 (the ?Effective Date?). ? RECITALS WHEREAS the parties desire for the Client to engage Consultant to perform the services described herein and for Consultant to provide such services on |
